COVID‐19 mortality in cirrhosis is determined by cirrhosis‐associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry

URN to cite this document:: urn:nbn:de:bvb:355-epub-576606
DOI to cite this document:: 10.5283/epub.57660

Brozat, Jonathan F.

; Hanses, Frank ; Haelberger, Martina ; Stecher, Melanie ; Dreher, Michael ; Tometten, Lukas ; Ruethrich, Maria M. ; Vehreschild, Janne J.

; Trautwein, Christian ; Borgmann, Stefan ; Vehreschild, Maria J. G. T.

; Jakob, Carolin E. M. ; Stallmach, Andreas ; Wille, Kai ; Hellwig, Kerstin ; Isberner, Nora ; Reuken, Philipp A. ; Geisler, Fabian ; Nattermann, Jacob ; Bruns, Tony

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
(555kB)

Date of publication of this fulltext: 29 Feb 2024 13:01

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Background and Objective International registries have reported high mortality rates in patients with liver disease and COVID-19. However, the extent to which comorbidities contribute to excess COVID-19 mortality in cirrhosis is controversial. Methods We used the multinational Lean European Open Survey on SARS-CoV-2-infected patients (LEOSS) to identify patients with cirrhosis documented between ...